24 Jan 2014 11:21
For Immediate Release 24 January 2014
Port Erin Biopharma Investments Limited
("Port Erin" or "the Company")
Holding in Company
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Port Erin Biopharma Investments Limited | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | X | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to thenotification obligation: iii | Colin Lee | |||
4. Full name of shareholder(s) (if different from 3.):iv | ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 23/01/2014 | |||
6. Date on which issuer notified: | 23/01/2014 | |||
7. Threshold(s) that is/are crossed orreached: vi, vii | 4% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
Ordinary 0.0001p
IM00B6QH1J21 | 1,354,700 | 1,354,700 | 1,304,700 | 1,304,700 | 3.85% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
1,307,700 | 3.85% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | |
| |
Proxy Voting: | |
10. Name of the proxy holder: | |
11. Number of voting rights proxy holder will ceaseto hold: | |
12. Date on which proxy holder will cease to holdvoting rights: | |
For further information, please visit the Company's website: www.porterinbiopharma.com or contact:
| |
Port Erin Biopharma Investments Limited Denham Eke
| Tel: +44 ( 0) 162 463 9396
|
Beaumont Cornish Limited Roland Cornish
| Tel: +44 (0) 20 7628 3396 |